Arrecife

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This condition involves abnormal growth of endometrial tissue outside the uterus and can cause chronic pelvic pain and infertility. The study compares sclerotherapy to expectant management to see which approach better improves pain and quality of life using the EHP-5 score. Participants will be randomly assigned to either the sclerotherapy group, which undergoes ultrasound-guided puncture and alcohol injection, or the control group, which receives expectant management without intervention. The study focuses on evaluating pain relief, quality of life, pregnancy rates, recurrence, adverse events, and treatment costs over six months. During the study, participants will complete pain and quality of life assessments at the start and after six months. They will also provide blood and urine samples for biomarker analysis and have ovarian reserve tests. Researchers will monitor safety, recurrence of endometriomas, fertility outcomes, and cost-effectiveness. The goal is to understand the benefits and risks of sclerotherapy compared to no treatment over this time period.

Researchers are evaluating inhaled sedation with isoflurane via the Sedaconda ACD-S system compared to intravenous sedation with propofol in critically ill patients who require mechanical ventilation. This phase IV, multicenter, randomized controlled trial focuses on patients expected to need more than 48 hours of invasive mechanical ventilation and aims to assess if isoflurane can reduce the duration of mechanical ventilation and ICU stay compared to propofol. Isoflurane has shown potential advantages in sedation but its long-term effects and outcomes in ICU patients are not fully understood. Participants will be randomly assigned to one of two groups: one receiving inhaled sedation with isoflurane administered via the Sedaconda ACD device and the other receiving intravenous sedation with propofol. Both treatments are administered to maintain a deep sedation level with a Richmond Agitation Sedation Scale (RASS) score between -3 and -5. The study includes 620 patients across 22 centers. The primary period involves sedation during mechanical ventilation, with monitoring continuing through the first 28 days after randomization. During the study, researchers will track ventilator-free days up to day 28 after randomization as the primary outcome. Secondary assessments include ICU-free days at day 28, time to extubation after sedation withdrawal, effectiveness in maintaining target sedation levels, need for additional hypnotics, delirium incidence and duration at day 28, and evaluations of mental, cognitive, and quality of life status at 90 days post-hospital discharge. Safety and efficacy data will be collected through clinical monitoring and cognitive assessments throughout the study period.